📌 The essentials On June 24, 2026, the FDA approved palbociclib (Ibrance, Pfizer) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment. This is palbociclib’s first approved use in HER2-positive disease. Palbociclib is already the most widely prescribed CDK4/6 inhibitor for HR-positive, HER2-negative metastatic breast cancer; this approval makes it the only CDK4/6 inhibitor approved for both HER2-negative and HER2-positive metastatic breast cancer. The “maintenance” context: the approved indication is for patients who have completed induction therapy (typically 4 to 8 cycles of a taxane plus trastuzumab, with or without pertuzumab) with no disease progression. They are not in response waiting for the next drug; they are in disease control continuing to their next treatment phase. Adding palbociclib at this point is what the trial tested. The clinical basis: Phase 3 PATINA trial (NCT02947685), published in the New England Journal of Medicine in January 2026. 518 patients, median follow-up 53.5 months, randomized 1:1 to palbociclib plus anti-HER2 therapy plus endocrine therapy versus anti-HER2 therapy plus endocrine therapy alone. Primary endpoint: PFS. Median PFS 44.3 months (95% CI 32.4 to 56.8) versus 29.1 months (95% CI 23.3 to 38.6). HR 0.75 (95% CI 0.59 to 0.96); 2-sided p=0.02. Risk reduction: 24% to 26% reduction in hazard of progression or death depending on analysis. 48-month PFS rate: 46.5% versus 38.3%. OS immature at time of analysis. Clinical benefit rate: 88.9% versus 80.9%. Median duration of confirmed response: 44.9 months versus 30.8 months. Regulatory designations: Breakthrough Therapy Designation. Dosing: 125 mg orally once daily for 21 consecutive days followed by 7 days off (3+1 schedule), matching established Ibrance dosing in HR-positive, HER2-negative disease. Endocrine therapy options in PATINA: fulvestrant, anastrozole, letrozole, or exemestane. Key safety: neutropenia most common (grade 3 or higher in approximately 61%); diarrhea 70%; infections 64%; febrile neutropenia 0.8%; serious adverse events 25%.

HR-positive, HER2-positive breast cancer accounts for approximately 10% of all breast cancers, but its clinical complexity is disproportionate to its prevalence. Unlike the more common HR-positive, HER2-negative subtype, which can be managed with endocrine therapy for years, or the HER2-positive, HR-negative subtype, which responds robustly to HER2-targeted regimens, this “double-positive” or “triple-positive” subtype presents a challenge that both its defining features create simultaneously.

The HER2 pathway and the estrogen receptor pathway engage in molecular cross-talk. Each can compensate for the other when the other is blocked. HER2-targeted therapy reduces HER2 signaling, but the estrogen receptor can maintain cell proliferation through alternative routes. Endocrine therapy reduces estrogen receptor signaling, but HER2 activity can bypass the growth arrest endocrine blockade would otherwise achieve. The result is that even patients who respond beautifully to first-line induction therapy often see their disease progress relatively quickly once the initial chemotherapy is removed.

The concept behind palbociclib’s PATINA approval is to add a third mechanism to the maintenance regimen that blocks a cell-cycle pathway that both HER2 and estrogen receptor signaling converge on: the CDK4/6 cyclin D1 axis. The Phase 3 PATINA trial tested this idea in 518 patients and demonstrated a 15-month improvement in median progression-free survival. The NEJM publication followed, and the FDA approved the regimen ahead of the PDUFA date on June 24, 2026.

---

What HR-Positive, HER2-Positive Breast Cancer Is and Why the Cross-Talk Problem Matters

Breast cancer is classified at diagnosis by three biomarkers that drive treatment selection: hormone receptor (HR) status, reflecting estrogen receptor (ER) and progesterone receptor (PR) expression; HER2 status, reflecting overexpression or gene amplification of the HER2 protein; and the Ki-67 proliferation index. Triple-positive (HR+/HER2+) disease expresses both hormone receptors and HER2 at clinically significant levels.

This dual positivity creates a therapeutic paradox. The two most productive targeted therapy approaches in breast cancer, endocrine therapy for HR-positive disease and HER2-directed biologics for HER2-positive disease, are both applicable but neither is fully sufficient on its own in the metastatic setting because each pathway can activate the other.

The ER-HER2 cross-talk operates through several mechanisms. Ligand-independent ER activation can occur downstream of HER2 signaling through PI3K/Akt and MAPK pathways, allowing tumor cells to maintain estrogen receptor activity even when estrogen levels are suppressed by aromatase inhibitors. Conversely, when HER2 signaling is blocked by trastuzumab or pertuzumab, upregulation of estrogen receptor signaling can compensate for the loss of HER2-driven proliferation. The cyclin D1-CDK4 axis sits at a convergence point for both pathways: both ER and HER2 signaling drive cyclin D1 expression, which activates CDK4/6 to push cells through the G1/S cell-cycle checkpoint and into DNA replication.

This convergence is the scientific rationale for the PATINA trial. As Dr. Otto Metzger, principal investigator, explained: “The cyclin D1-CDK4 axis is essential for initiation and maintenance of growth in HER2-positive disease. The same axis drives resistance to the HER2 pathway blockade. Combined CDK4/6 and HER2 inhibition has shown to be synergistic and to have a profound antitumor activity in preclinical models.” Las Vegas Sun

The standard first-line treatment context

The current standard first-line regimen for HR-positive, HER2-positive locally advanced or metastatic breast cancer is induction with a taxane plus trastuzumab, with or without pertuzumab, for typically 4 to 8 cycles. Patients who achieve disease control then transition to maintenance therapy with continuation of the anti-HER2 regimen plus endocrine therapy. This is the established, evidence-based platform on which PATINA builds.

The PATINA trial asked a specific maintenance question: after induction has achieved disease control, does adding palbociclib to the established maintenance regimen (anti-HER2 therapy plus endocrine therapy) extend the time before the disease progresses?

---

How Palbociclib Works: CDK4/6 Inhibition and Why It Is Relevant in HER2-Positive Disease

Palbociclib is an oral inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). CDK4 and CDK6 are kinases that, when activated by their regulatory partners cyclin D1, phosphorylate the retinoblastoma protein (Rb). Phosphorylated Rb releases the transcription factor E2F, which then drives expression of genes needed for DNA synthesis and cell division. This CDK4/6-Rb-E2F pathway is a fundamental cell-cycle checkpoint: it governs the transition from G1 (growth phase) to S phase (DNA synthesis), a critical commitment point in the decision to divide.

When CDK4/6 is inhibited by palbociclib, Rb remains underphosphorylated, E2F remains sequestered, and the cell cannot progress to DNA synthesis. The result is cell-cycle arrest, predominantly in G1, followed by either senescence or cell death in tumor cells that depend on this pathway for proliferation.

In HR-positive, HER2-negative breast cancer, CDK4/6 inhibitors have been the standard of care in combination with endocrine therapy since palbociclib’s initial 2015 approval, establishing the principle that blocking the cell cycle downstream of estrogen receptor signaling extends disease control. The question the PATINA trial addressed is whether this principle extends to HR-positive, HER2-positive disease, where HER2 signaling is an additional upstream driver of CDK4/6 activation.

The preclinical and biological evidence suggests it should. Both ER and HER2 signaling drive cyclin D1 expression. Blocking CDK4/6 downstream of both pathways simultaneously, in combination with anti-HER2 therapy and endocrine therapy, addresses the pathway cross-talk from a third convergence point. PATINA provided the Phase 3 confirmation.

---

The PATINA Trial: Design and Full Results

Design

PATINA (NCT02947685) was a Phase 3, randomized, open-label trial sponsored by Alliance Foundation Trials in partnership with multiple academic cooperative groups globally (Breast Cancer Trials, Fondazione Michelangelo, GBG Forschungs, PrECOG, SOLTI, and Unicancer), with funding from Pfizer.

Eligibility: Adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer who had no evidence of disease progression after induction treatment with a taxane plus trastuzumab, with or without pertuzumab, for their advanced disease. This is a strictly defined post-induction maintenance population.

Randomization: 1:1, 518 patients total (261 palbociclib arm; 257 control arm).

Treatment:

• Palbociclib arm: palbociclib 125 mg orally once daily (days 1 to 21 of a 28-day cycle) plus trastuzumab every 3 weeks (with or without pertuzumab) plus endocrine therapy (fulvestrant, anastrozole, letrozole, or exemestane per investigator choice)
• Control arm: trastuzumab every 3 weeks (with or without pertuzumab) plus endocrine therapy alone

Both arms continued until progressive disease or unacceptable toxicity.

Primary endpoint: Progression-free survival (PFS). Note on analysis: the FDA approval cites the primary PFS as reported in the NEJM publication with HR 0.75 and 2-sided p=0.02, while the original SABCS 2024 presentation reported unstratified HR 0.74 and 1-sided p=0.0074. Both reflect the same trial data at different analysis timepoints and stratification approaches. The NEJM publication, at a median follow-up of 53.5 months, is the most mature analysis.

Trial published: New England Journal of Medicine, January 2026. doi:10.1056/NEJMoa2511218.

Primary results

Endpoint	Palbociclib arm	Control arm	Result
Median PFS	44.3 months (95% CI 32.4 to 56.8)	29.1 months (95% CI 23.3 to 38.6)	HR 0.75 (95% CI 0.59 to 0.96); 2-sided p=0.02
Risk reduction in progression or death	25%	Reference	—
48-month PFS rate	46.5%	38.3%	—
Median follow-up	53.5 months	—	—
Clinical benefit rate	88.9%	80.9%	—
Median duration of confirmed response	44.9 months	30.8 months	—
Overall survival	Not mature	Not mature	No OS detriment observed

Source: Metzger O et al. Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer. NEJM. 2026;394(5):451-462. doi:10.1056/NEJMoa2511218. PATINA NCT02947685.

A 15.2-month improvement in median PFS (44.3 versus 29.1 months) is a clinically substantial finding in the maintenance setting. To put this in context: the control arm’s median PFS of 29.1 months is itself a historically strong result, reflecting the effectiveness of the established dual anti-HER2 plus endocrine maintenance platform. Improving upon a 29-month median PFS is considerably harder than improving upon shorter medians seen in earlier-line trials. The palbociclib arm reaching 44.3 months represents disease control sustained for approximately 3 years and 8 months on average after completing induction.

As Dr. Metzger noted: “The ability to meaningfully extend progression-free survival with a well-tolerated regimen offers new hope for individuals living with this challenging subtype of metastatic breast cancer.” The Hill

Open-label design: an important interpretive note

PATINA was an open-label trial, meaning patients and investigators knew which treatment arm each patient was on. PFS was assessed by investigator rather than blinded independent central review in some analyses. An open-label design may introduce assessment bias in investigator-determined PFS, and this is a legitimate limitation to acknowledge alongside the results. However, PFS is a validated surrogate endpoint in metastatic breast cancer with strong regulatory acceptance, and the statistical significance and magnitude of the benefit are both clinically meaningful. The FDA reviewed these data and determined they were sufficient for approval. FDA

OS data remain immature. Whether the PFS benefit in PATINA translates into an overall survival advantage will require continued follow-up. Given the extensive use of subsequent therapies including ADCs such as trastuzumab deruxtecan and other agents in patients who progress on both arms, the OS signal may be attenuated regardless of true treatment benefit, a well-recognized challenge in metastatic breast cancer trials.

---

What This Approval Means in the Broader Breast Cancer Treatment Landscape

The “double-positive” disease positioning

The approval fills a specific gap in the treatment landscape for HR-positive, HER2-positive metastatic breast cancer. Until this approval, CDK4/6 inhibitors were reserved for HER2-negative disease. Patients with dual-positive disease who responded to induction had no CDK4/6 inhibitor option in the maintenance phase. The assumption that CDK4/6 inhibition provided no benefit in the presence of active HER2 targeting has now been disproven by PATINA.

This approval does not position palbociclib as part of the induction regimen alongside chemotherapy and anti-HER2 therapy. It is a post-induction maintenance addition for patients who have demonstrated disease control. The sequencing is important: induction first, then reassess, then add palbociclib to maintenance if the patient has no evidence of progression and is suitable for the oral dosing regimen.

Palbociclib’s expanded indication scope

Before June 24, 2026, palbociclib was approved for:

• HR-positive, HER2-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy (women and men)
• HR-positive, HER2-negative locally advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy

After June 24, 2026, palbociclib also covers:

• HR-positive, HER2-positive locally advanced or metastatic breast cancer in combination with trastuzumab (with or without pertuzumab) and endocrine therapy in the maintenance setting following induction

This makes Ibrance the only CDK4/6 inhibitor indicated for HR-positive metastatic breast cancer regardless of HER2 status, a commercially and clinically meaningful distinction.

How this compares to other treatment options in HR-positive, HER2-positive disease

The treatment landscape for HR-positive, HER2-positive metastatic breast cancer also includes trastuzumab deruxtecan (Enhertu), an ADC with substantial activity in this subtype and approvals in both first-line (after platinum-based chemotherapy) and later-line settings. The PATINA approval does not directly compete with trastuzumab deruxtecan in sequencing terms, as the indications are different: PATINA covers post-induction maintenance for disease-controlled patients, while trastuzumab deruxtecan’s indications cover patients with progressive or later-line disease.

The practical question for oncologists managing newly diagnosed HR-positive, HER2-positive metastatic disease is now: in a patient completing induction without progression, should palbociclib be added to the standard anti-HER2 plus endocrine maintenance? PATINA says yes, with a 25% risk reduction and a 15-month median PFS improvement. OS data, which will clarify the survival benefit, are pending.

---

Safety: What the PATINA Data and Prescribing Information Cover

The safety profile of palbociclib in PATINA was consistent with its established profile in HR-positive, HER2-negative breast cancer, dominated by predictable and manageable hematologic toxicity from CDK4/6 inhibition.

Safety item	Rate in PATINA (palbociclib arm)	Clinical guidance
Neutropenia (all grades)	78%	CBC monitoring before each cycle; dose interruption or reduction per prescribing information for grade 3 or higher neutropenia
Neutropenia (grade 3 or higher)	61%	G-CSF not routinely required but may be used; febrile neutropenia rate was low (0.8%)
Diarrhea	70%	Predominantly mild; anti-diarrheal agents as needed; dose modification for grade 3 or higher
Infections	64%	Predominantly mild to moderate upper respiratory infections; monitor for serious infections
Serious adverse events	25%	Clinical monitoring; follow prescribing information dose modification guidance
Febrile neutropenia	0.8%	Low absolute rate despite high neutropenia frequency; reflects manageable neutropenia depth
Interstitial lung disease/pneumonitis	Identified class risk (prescribing information warning)	Monitor for new or worsening pulmonary symptoms; hold palbociclib and evaluate promptly

Boxed warning equivalent class precautions and warnings (from Ibrance prescribing information):

Neutropenia: The most common and clinically significant toxicity. Grade 3 or higher neutropenia occurred in approximately 61% of PATINA palbociclib-treated patients. CBC should be checked before starting and at the beginning of each cycle, on day 15 of the first two cycles, and as clinically indicated. Dose modification is recommended for grade 3 and required for grade 4 neutropenia or febrile neutropenia.

Interstitial lung disease (ILD) and pneumonitis: Cases of ILD and pneumonitis have been reported with palbociclib, some resulting in fatal outcomes. Patients should be monitored for pulmonary symptoms. Palbociclib should be held for grade 2 or higher ILD/pneumonitis events and permanently discontinued for grade 3 or higher.

Embryo-fetal toxicity: Ibrance can cause fetal harm. Females of reproductive potential should use effective contraception during treatment and for 3 weeks after the last dose. Males with female partners of reproductive potential should use effective contraception during treatment and for 3 months after the last dose.

CYP3A interactions: Palbociclib is primarily metabolized by CYP3A. Strong CYP3A inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit products) increase palbociclib exposure. Strong CYP3A inducers (rifampin, phenytoin, carbamazepine, St. John’s wort) decrease palbociclib exposure. Avoid strong CYP3A inhibitors and inducers during palbociclib therapy; if unavoidable, dose adjustments apply.

---

Dosing and Administration

The approved maintenance dose of palbociclib for this indication is the standard established dose used across all Ibrance indications:

• 125 mg orally once daily for 21 consecutive days, followed by 7 days off (3-week on, 1-week off cycle)
• Can be taken with or without food
• Capsules should be swallowed whole; not chewed, opened, or crushed
• If a dose is vomited or missed, do not take an additional dose that day; take the next dose at the scheduled time

This dosing schedule is the same as palbociclib’s dosing in HR-positive, HER2-negative disease, and oncology teams familiar with Ibrance management will not encounter a learning curve for the maintenance regimen.

---

What This Means for Patients and Oncology Teams

For patients currently completing first-line induction for HR-positive, HER2-positive metastatic breast cancer

If you have completed induction therapy with a taxane plus trastuzumab (with or without pertuzumab) and your cancer has not progressed, you are now in the population for which palbociclib maintenance is FDA-approved. A conversation with your oncologist about whether adding palbociclib to your maintenance regimen is appropriate for your individual situation should be part of your post-induction treatment planning discussion.

The practical considerations include your current neutrophil count and blood counts (given palbociclib’s neutropenia risk), other medications that may interact with CYP3A, and your overall tolerance of the 3-week-on/1-week-off oral dosing schedule.

For oncology teams

PATINA establishes palbociclib as a new maintenance option after induction in HR-positive, HER2-positive metastatic breast cancer, with the following key clinical parameters: the trial required no evidence of progression after completing induction with a taxane and anti-HER2 therapy; patients were on full anti-HER2 maintenance (trastuzumab with or without pertuzumab) plus endocrine therapy; palbociclib was added at standard dosing; and the PFS benefit was 15 months in median with a 25% risk reduction.

The open-label design and investigator-assessed PFS are limitations worth discussing with patients in the shared decision-making conversation. The absence of mature OS data means that the long-term survival benefit remains to be established. The neutropenia management framework for palbociclib is well-established from the HR-positive, HER2-negative experience, and PATINA’s low febrile neutropenia rate (0.8%) suggests the toxicity is manageable in this population as well.

For related HED coverage on breast cancer approvals and ADC therapies in oncology, see our post on Trodelvy (sacituzumab govitecan) receiving two new first-line approvals for metastatic TNBC approved on the same day as this palbociclib indication.

---

Sources

FDA approval announcement: FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer. FDA.gov. June 24, 2026.

PATINA NEJM primary publication: Metzger O et al. Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer. New England Journal of Medicine. 2026;394(5):451-462. doi:10.1056/NEJMoa2511218.

PATINA trial registration: NCT02947685. ClinicalTrials.gov.

CancerNetwork approval summary (with full PFS data): FDA Approves Palbociclib Combo in HR+, HER2+ Metastatic Breast Cancer. cancernetwork.com. June 2026.

CancerNetwork PATINA full results summary: Palbociclib Maintenance Extends PFS in HR+/HER2+ Advanced Breast Cancer. cancernetwork.com. 2026.

ASCO Post SABCS 2024 presentation coverage: Addition of Palbociclib to Standard Therapy in Metastatic HR-Positive HER2-Positive Breast Cancer. ascopost.com.

OncLive primary investigator commentary: Palbociclib Plus Anti-HER2 and Endocrine Therapy Prolongs PFS in HR+/HER2+ Breast Cancer. onclive.com.

Pharmacy Times clinical review: FDA Approves Palbociclib-Based Maintenance Regimen for HR-Positive, HER2-Positive Metastatic Breast Cancer. pharmacytimes.com. June 2026.

PharmExec analytical summary (with design caveats): Ibrance Wins FDA Approval for HR-Positive, HER2-Positive Metastatic Breast Cancer Maintenance Therapy. pharmexec.com. June 2026.

Medscape clinical coverage: Palbociclib Gains HER2+ Breast Cancer Maintenance Indication. medscape.com. June 2026.

Epocrates clinical brief: FDA approves Ibrance maintenance combo for HR-positive, HER2-positive metastatic breast cancer. epocrates.com. June 2026.

PrECOG NEJM publication announcement: New England Journal of Medicine publishes phase 3 PATINA trial data. precogllc.org. January 2026.

ONS clinical summary: FDA Approves Palbociclib Combination for Maintenance Treatment of HR-Positive, HER2-Positive Metastatic Breast Cancer. ons.org. June 2026.

Palbociclib StatPearls: Palbociclib. StatPearls. NCBI.

Breast cancer biology and HER2: Breast Cancer Overview. StatPearls. NCBI.

Ibrance prescribing information: IBRANCE (palbociclib) Prescribing Information. Pfizer. 2026.

Trastuzumab/pertuzumab: FDA approves pertuzumab, trastuzumab, and hyaluronidase-zzxf for HER2-positive breast cancer. FDA.gov.

Patient resources: National Breast Cancer Foundation | Susan G. Komen Foundation | Pfizer Ibrance patient support | American Cancer Society: Breast Cancer Types

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Decisions about maintenance therapy for HR-positive, HER2-positive metastatic breast cancer, including the addition of palbociclib following induction, require individualized assessment by a board-certified medical oncologist experienced in breast cancer management. Drug pricing information reflects figures at time of publication and is subject to change.